Clinical Data Preliminary findings from the ADXS-NEO Phase 1 study include the following:

• Substantial anti-tumor immunity, including T cell responses to neoantigens and antigen spreading, was observed within one week of first dose at both dose levels
• Dosing of ADXS-NEO at 1x108 colony forming units (CFU) has been well-tolerated in two patients
• ADXS-NEO dosed at 1x109 CFU was beyond the maximum tolerated dose (MTD)
  • Reversible Grade 3 hypoxia (n=2) and Grade 3 hypotension (n=1) were dose-limiting toxicities (DLTs)
• Manufacturing of ADXS-NEO, comprised of 40 personal neoantigens, was successfully completed within seven to eight weeks for each subject